Skip to main content
Top
Published in:

26-12-2023 | Pneumonia | Research

High prevalence of pneumocystis pneumonia in interstitial lung disease: a retrospective study

Authors: Ling Liu, Tong Ji, Ranxun Chen, Li Fan, Jinghong Dai, Yuying Qiu

Published in: Infection | Issue 3/2024

Login to get access

Abstract

Background

Interstitial lung disease (ILD) is a new risk category for pneumocystis pneumonia (PCP) with a high mortality rate. The definite diagnostic criteria of PCP in ILD patients have not been established until now. The aims of this study were to identify potential risk factors of PCP in patients with ILD, and to evaluate the performance of metagenomic next-generation sequencing (mNGS), CD4 + T cell count, (1–3)-β-d-Glucan (BG) and lactate dehydrogenase (LDH) in the diagnosis of PCP in ILD patients.

Methods

This is a retrospective, single-center, case–control study. ILD patients who underwent mNGS from December 2018 to December 2022 were included in the study. Based on the diagnosis criteria of PCP, these patients were divided into PCP-ILD and non-PCP-ILD groups. The potential risk factors for PCP occurrence in ILD patients were analysed via logistic regression. The diagnostic efficacy of mNGS was compared with serological biomarkers.

Results

92 patients with ILD were enrolled, 31 of which had a definite PCP and were assigned to the PCP-ILD group while 61 were to the non-PCP-ILD group. The infection rate of PJ in ILD patients was 33.7% (31/92). The history of glucocorticoid therapy, CD4 + T cell count, BG level and traction bronchiectasis on HRCT were associated with PCP occurrence in ILD patients. LDH level did not reach statistical significance in the logistic regression analysis. mNGS was confirmed as the most accurate test for PCP diagnosis in ILD patients.

Conclusion

ILD is a new risk group of PCP with high PCP prevalence. Clinicians should pay close attention to the occurrence of PCP in ILD patients who possess the risk factors of previous glucocorticoid therapy, decreased CD4 + T cell count, increased BG level and absence of traction bronchiectasis on HRCT. mNGS showed the most excellent performance for PCP diagnosis in ILD patients. Peripheral blood CD4 + T cell count and BG level are alternative diagnostic methods for PCP in ILD patients. However, the diagnostic value of serum LDH level was limited in ILD patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies. Intern Med J. 2014;44:1350–63.CrossRefPubMed Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies. Intern Med J. 2014;44:1350–63.CrossRefPubMed
2.
go back to reference Xixia C, Xiaoming S, Linrong H, et al. High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody- positive dermatomyositis. Rheumatology. 2023; 62:3302–9.CrossRef Xixia C, Xiaoming S, Linrong H, et al. High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody- positive dermatomyositis. Rheumatology. 2023; 62:3302–9.CrossRef
3.
go back to reference Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Cordonnier C, Maertens J, Bretagne S, 5th European Conference on Infections in Leukemia (ECIL-5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2386–96.CrossRefPubMed Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Cordonnier C, Maertens J, Bretagne S, 5th European Conference on Infections in Leukemia (ECIL-5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2386–96.CrossRefPubMed
4.
go back to reference Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014;127:1242e11-1243e17.CrossRef Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014;127:1242e11-1243e17.CrossRef
5.
go back to reference Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest. 2005;128:573–539.CrossRefPubMed Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest. 2005;128:573–539.CrossRefPubMed
7.
go back to reference Vidal S, de la Horra C, Martín J, et al. Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect. 2006;12:231–5.CrossRefPubMed Vidal S, de la Horra C, Martín J, et al. Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect. 2006;12:231–5.CrossRefPubMed
8.
go back to reference Hamada S, Ichiyasu H, Inaba M, Takahashi H, Sadamatsu T, Akaike K, Masunaga A, Tashiro Y, Hirata N, Yoshinaga T, Sakagami T. Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia. ERJ Open Res. 2020;6:00306–2019.CrossRefPubMedPubMedCentral Hamada S, Ichiyasu H, Inaba M, Takahashi H, Sadamatsu T, Akaike K, Masunaga A, Tashiro Y, Hirata N, Yoshinaga T, Sakagami T. Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia. ERJ Open Res. 2020;6:00306–2019.CrossRefPubMedPubMedCentral
10.
go back to reference Rego de Figueiredo I, Vieira Alves R, Drummond Borges D, et al. Pneumocystosis pneumonia: a comparison study between HIV and non-HIV immunocompromised patients. Pulmonology. 2019;25:271–4.CrossRefPubMed Rego de Figueiredo I, Vieira Alves R, Drummond Borges D, et al. Pneumocystosis pneumonia: a comparison study between HIV and non-HIV immunocompromised patients. Pulmonology. 2019;25:271–4.CrossRefPubMed
11.
go back to reference Yuxin S, Chi S, Hui H, et al. Prognostic analysis of Pneumocystis jirovecii pneumonia in interstitial lung disease patients: a retrospective clinical study. Diagnostics. 2022;12:2925.CrossRef Yuxin S, Chi S, Hui H, et al. Prognostic analysis of Pneumocystis jirovecii pneumonia in interstitial lung disease patients: a retrospective clinical study. Diagnostics. 2022;12:2925.CrossRef
12.
go back to reference Sokulska M, Kicia M, Wesołowska M, Hendrich AB. Pneumocystis jirovecii–from a commensal to pathogen: clinical and diagnostic review. Parasitol Res. 2015;114:3577–85.CrossRefPubMedPubMedCentral Sokulska M, Kicia M, Wesołowska M, Hendrich AB. Pneumocystis jirovecii–from a commensal to pathogen: clinical and diagnostic review. Parasitol Res. 2015;114:3577–85.CrossRefPubMedPubMedCentral
14.
go back to reference Xie Y, Du J, Jin W, et al. Next generation sequencing for diagnosis of severe Pneumonia: China, 2010–2018. J Infect. 2019;78:158–69.CrossRefPubMed Xie Y, Du J, Jin W, et al. Next generation sequencing for diagnosis of severe Pneumonia: China, 2010–2018. J Infect. 2019;78:158–69.CrossRefPubMed
15.
go back to reference Liu N, Kan J, Yu N, Cao W, Cao J, Jiang E, Feng J. Application of metagenomic next-generation sequencing technology for difficult lung lesions in patients with haematological diseases. Transl Cancer Res. 2020;9:5245–54.CrossRefPubMedPubMedCentral Liu N, Kan J, Yu N, Cao W, Cao J, Jiang E, Feng J. Application of metagenomic next-generation sequencing technology for difficult lung lesions in patients with haematological diseases. Transl Cancer Res. 2020;9:5245–54.CrossRefPubMedPubMedCentral
16.
go back to reference Chen J, He T, Li X, Wang X, Peng L, Ma L. Metagenomic next-generation sequencing in diagnosis of a case of Pneumocystis jirovecii pneumonia in a kidney transplant recipient and literature review. Infect Drug Resist. 2020;13:2829–36.CrossRefPubMedPubMedCentral Chen J, He T, Li X, Wang X, Peng L, Ma L. Metagenomic next-generation sequencing in diagnosis of a case of Pneumocystis jirovecii pneumonia in a kidney transplant recipient and literature review. Infect Drug Resist. 2020;13:2829–36.CrossRefPubMedPubMedCentral
17.
go back to reference Anan K, Oshima Y, Ogura T, Tanabe Y, Higashi A, Iwashita Y, Fujita K, Yoshida T, Ando K, Okamori S, Okada Y. Safety and harms of bronchoalveolar lavage for acute respiratory failure: a systematic review and meta-analysis. Respir Investig. 2022;60:68–81.CrossRefPubMed Anan K, Oshima Y, Ogura T, Tanabe Y, Higashi A, Iwashita Y, Fujita K, Yoshida T, Ando K, Okamori S, Okada Y. Safety and harms of bronchoalveolar lavage for acute respiratory failure: a systematic review and meta-analysis. Respir Investig. 2022;60:68–81.CrossRefPubMed
18.
go back to reference Esteves F, Cale SS, Badura R, et al. Diagnosis of Pneumocystis pneumonia: evaluation of four serologic biomarkers. Clin Microbiol Infect. 2015;21:e110-379.e10.CrossRef Esteves F, Cale SS, Badura R, et al. Diagnosis of Pneumocystis pneumonia: evaluation of four serologic biomarkers. Clin Microbiol Infect. 2015;21:e110-379.e10.CrossRef
19.
go back to reference Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009;9:47.CrossRefPubMedPubMedCentral Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009;9:47.CrossRefPubMedPubMedCentral
20.
go back to reference Damiani C, Le Gal S, Da Costa C, Virmaux M, Nevez G, Totet A. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-β-D-glucan for differential diagnosis of Pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol. 2013;51:3380–8.CrossRefPubMedPubMedCentral Damiani C, Le Gal S, Da Costa C, Virmaux M, Nevez G, Totet A. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-β-D-glucan for differential diagnosis of Pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol. 2013;51:3380–8.CrossRefPubMedPubMedCentral
21.
go back to reference White PL, Backx M, Barnes RA. Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther. 2017;15:435–47.CrossRefPubMed White PL, Backx M, Barnes RA. Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther. 2017;15:435–47.CrossRefPubMed
22.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMedPubMedCentral Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMedPubMedCentral
23.
go back to reference Wissmann G, Morilla R, Friaza V, Calderón E, Varela JM. El ser humano como reservorio de Pneumocystis [Human reservoirs of Pneumocystis]. Enferm Infecc Microbiol Clin. 2010;28:38–43.CrossRefPubMed Wissmann G, Morilla R, Friaza V, Calderón E, Varela JM. El ser humano como reservorio de Pneumocystis [Human reservoirs of Pneumocystis]. Enferm Infecc Microbiol Clin. 2010;28:38–43.CrossRefPubMed
24.
go back to reference Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother. 2012;18:793–806.CrossRefPubMed Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother. 2012;18:793–806.CrossRefPubMed
25.
go back to reference Chen H, Tan C, Wang Z, Zha J, Liu H, Dong Z, Chen G. Long-term glucocorticoid exposure persistently impairs CD4+ T cell biology by epigenetically modulating the mTORC1 pathway. Biochem Pharmacol. 2023;211: 115503.CrossRefPubMed Chen H, Tan C, Wang Z, Zha J, Liu H, Dong Z, Chen G. Long-term glucocorticoid exposure persistently impairs CD4+ T cell biology by epigenetically modulating the mTORC1 pathway. Biochem Pharmacol. 2023;211: 115503.CrossRefPubMed
26.
go back to reference Yamaguchi T, Nagai Y, Morita T, et al. Pneumocystis pneumonia in patients treated with long-term steroid therapy for symptom palliation: a neglected infection in palliative care. Am J Hosp Palliat Care. 2014;31:857–61.CrossRefPubMed Yamaguchi T, Nagai Y, Morita T, et al. Pneumocystis pneumonia in patients treated with long-term steroid therapy for symptom palliation: a neglected infection in palliative care. Am J Hosp Palliat Care. 2014;31:857–61.CrossRefPubMed
27.
go back to reference Plakke MJ, Jalota L, Lloyd BJ. Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis. BMJ Case Rep. 2013; 2013: bcr2012007912.CrossRefPubMedPubMedCentral Plakke MJ, Jalota L, Lloyd BJ. Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis. BMJ Case Rep. 2013; 2013: bcr2012007912.CrossRefPubMedPubMedCentral
28.
go back to reference Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5–13.CrossRefPubMed Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5–13.CrossRefPubMed
29.
go back to reference Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:1052–9.CrossRefPubMed Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:1052–9.CrossRefPubMed
30.
go back to reference Messiaen PE, Cuyx S, Dejagere T, van der Hilst JC. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review. Transpl Infect Dis. 2017;19:66.CrossRef Messiaen PE, Cuyx S, Dejagere T, van der Hilst JC. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review. Transpl Infect Dis. 2017;19:66.CrossRef
31.
go back to reference Huang L, Xu S, Huang Z, Chen Y, Xu N, Xie B. Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing. BMC Pulm Med. 2023;23:72.CrossRefPubMedPubMedCentral Huang L, Xu S, Huang Z, Chen Y, Xu N, Xie B. Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing. BMC Pulm Med. 2023;23:72.CrossRefPubMedPubMedCentral
32.
go back to reference Li Y, Ghannoum M, Deng C, Gao Y, Zhu H, Yu X, Lavergne V. Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: usefulness of lymphocyte subtyping. Int J Infect Dis. 2017;57:108–15.CrossRefPubMed Li Y, Ghannoum M, Deng C, Gao Y, Zhu H, Yu X, Lavergne V. Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: usefulness of lymphocyte subtyping. Int J Infect Dis. 2017;57:108–15.CrossRefPubMed
33.
go back to reference Mori S, Sugimoto M. Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations. Clin Med Insights Circ Respir Pulm Med. 2015;9:29–40.PubMedPubMedCentral Mori S, Sugimoto M. Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations. Clin Med Insights Circ Respir Pulm Med. 2015;9:29–40.PubMedPubMedCentral
34.
go back to reference Alanio A, Desoubeaux G, Sarfati C, Hamane S, Bergeron A, Azoulay E, Molina JM, Derouin F, Menotti J. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect. 2011;17:1531–7.CrossRefPubMed Alanio A, Desoubeaux G, Sarfati C, Hamane S, Bergeron A, Azoulay E, Molina JM, Derouin F, Menotti J. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect. 2011;17:1531–7.CrossRefPubMed
35.
go back to reference Dichtl K, Seybold U, Wagener J. Evaluation of a turbidimetric β-d-glucan test for detection of Pneumocystis jirovecii pneumonia. J Clin Microbiol. 2018;56:e00286-e318.CrossRefPubMedPubMedCentral Dichtl K, Seybold U, Wagener J. Evaluation of a turbidimetric β-d-glucan test for detection of Pneumocystis jirovecii pneumonia. J Clin Microbiol. 2018;56:e00286-e318.CrossRefPubMedPubMedCentral
36.
go back to reference Engsbro AL, Najat S, Jørgensen KM, Kurtzhals JAL, Arendrup MC. Diagnostic accuracy of the 1,3-β-D-glucan test for pneumocystis pneumonia in a tertiary university hospital in Denmark: a retrospective study. Med Mycol. 2019;57:710–7.CrossRefPubMed Engsbro AL, Najat S, Jørgensen KM, Kurtzhals JAL, Arendrup MC. Diagnostic accuracy of the 1,3-β-D-glucan test for pneumocystis pneumonia in a tertiary university hospital in Denmark: a retrospective study. Med Mycol. 2019;57:710–7.CrossRefPubMed
37.
go back to reference Del Corpo O, Butler-Laporte G, Sheppard DC, Cheng MP, McDonald EG, Lee TC. Diagnostic accuracy of serum (1–3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26:1137–43.CrossRefPubMed Del Corpo O, Butler-Laporte G, Sheppard DC, Cheng MP, McDonald EG, Lee TC. Diagnostic accuracy of serum (1–3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26:1137–43.CrossRefPubMed
38.
go back to reference Kutty G, Davis AS, Ferreyra GA, Qiu J, da Huang W, Sassi M, Bishop L, Handley G, Sherman B, Lempicki R, Kovacs JA. β-Glucans are masked but contribute to pulmonary inflammation during pneumocystis pneumonia. J Infect Dis. 2016;214:782–91.CrossRefPubMedPubMedCentral Kutty G, Davis AS, Ferreyra GA, Qiu J, da Huang W, Sassi M, Bishop L, Handley G, Sherman B, Lempicki R, Kovacs JA. β-Glucans are masked but contribute to pulmonary inflammation during pneumocystis pneumonia. J Infect Dis. 2016;214:782–91.CrossRefPubMedPubMedCentral
39.
go back to reference Parize P, Muth E, Richaud C, et al. Untargeted next-generation sequencing-based first-line diagnosis of infection in immunocompromised adults: a multicentre, blinded, prospective study. Clin Microbiol Infect. 2017;23:574.e1-574.e6.CrossRefPubMed Parize P, Muth E, Richaud C, et al. Untargeted next-generation sequencing-based first-line diagnosis of infection in immunocompromised adults: a multicentre, blinded, prospective study. Clin Microbiol Infect. 2017;23:574.e1-574.e6.CrossRefPubMed
40.
go back to reference Jiang J, Bai L, Yang W, Peng W, An J, Wu Y, Pan P, Li Y. Metagenomic next-generation sequencing for the diagnosis of Pneumocystis jirovecii pneumonia in non-HIV-infected patients: a retrospective study. Infect Dis Ther. 2021;10:1733–45.CrossRefPubMedPubMedCentral Jiang J, Bai L, Yang W, Peng W, An J, Wu Y, Pan P, Li Y. Metagenomic next-generation sequencing for the diagnosis of Pneumocystis jirovecii pneumonia in non-HIV-infected patients: a retrospective study. Infect Dis Ther. 2021;10:1733–45.CrossRefPubMedPubMedCentral
Metadata
Title
High prevalence of pneumocystis pneumonia in interstitial lung disease: a retrospective study
Authors
Ling Liu
Tong Ji
Ranxun Chen
Li Fan
Jinghong Dai
Yuying Qiu
Publication date
26-12-2023
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 3/2024
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-023-02148-y

Other articles of this Issue 3/2024

Infection 3/2024 Go to the issue

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more